Sanara MedTech Inc. (SMTI) 株式分析

企業概要

Sanara MedTech Inc. is a medical technology firm dedicated to the development, marketing, and distribution of surgical solutions for physicians, hospitals, and clinics across the United States. The company operates within the Healthcare sector, specifically focusing on the Medical Instruments & Supplies industry, which involves providing essential equipment and materials for medical procedures. As of the latest data, the entity maintains a market capitalization of $155.84M, generates annual revenue of $103.12M, and employs a workforce of 108 individuals. These valuation figures indicate that the company holds a mid-cap position in its niche, suggesting a level of established market presence that balances between small-cap agility and large-cap stability. The scale of operations, reflected by the revenue and employee count, points to a structured organization capable of supporting a specialized product portfolio without the overhead of a massive enterprise.

財務健全性

The company reported a revenue of $103.12M for the trailing twelve months, yet posted a net income of $-387,683, while generating an EBITDA of $11.81M. The significant discrepancy between positive revenue and negative net income reveals a cost structure where operating expenses or interest costs are absorbing nearly the entire pre-tax profit, resulting in a loss at the bottom line despite strong operational cash generation. Sanara MedTech Inc. demonstrated financial flexibility with a free cash flow of $8.54M, indicating that the core business operations are generating sufficient cash to cover capital expenditures and potentially fund internal growth initiatives. The firm holds a cash reserve of $16.58M against a total debt load of $48.19M, highlighting a leveraged balance sheet where liabilities exceed liquid assets. The debt-to-equity ratio stands at 812.73, which is an exceptionally high figure suggesting the company is heavily reliant on debt financing relative to its equity base. Liquidity is supported by a current ratio of 1.80, indicating that the company possesses $1.80 in current assets for every $1.00 of current liabilities, providing a comfortable buffer for short-term obligations. Return metrics show a Return on Equity of -1.8% and a Return on Assets of 7.1%, revealing that while asset utilization is efficient enough to generate a positive return on the asset base, shareholder value is currently being eroded due to the net loss position.

バリュエーション評価

The trailing twelve-month P/E ratio is listed as N/A due to the net loss, whereas the forward P/E is reported as -14.53, implying that the market is pricing in a return to profitability or specific analyst expectations regarding future earnings per share. The price-to-book ratio is 25.60, which indicates that the market is valuing the company at a significant premium over its tangible book value, a common characteristic in growth-oriented or technology-driven healthcare sectors where intangible assets drive value. Alternative valuation metrics include a price-to-sales ratio of 1.51 and an EV/EBITDA of 15.88, suggesting that investors are willing to pay a substantial multiple of sales and enterprise value relative to earnings before interest, taxes, depreciation, and amortization. The stock has traded between a 52-week high of $35.95 and a 52-week low of $16.05, and without a specific current price provided in the facts, the valuation range indicates the volatility experienced over the last year. The beta value of 1.10 suggests that the stock's price volatility is 10% higher than the broader market, reflecting sensitivity to general market fluctuations.

Growth & Income

Sanara MedTech Inc. achieved a revenue growth of 4.7% year-over-year, while the earnings growth is listed as N/A due to the current net loss. Since earnings are negative, they cannot be growing faster than revenue in a traditional sense; instead, the focus remains on scaling revenue while managing the high fixed costs associated with the medical instrument industry. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available earnings are theoretically reinvested into operations or retained to reduce the substantial debt load. This reinvestment strategy is typical for companies in the development or expansion phase where capital is prioritized for R&D and market penetration rather than shareholder distributions. The overall growth and income profile reflects a capital-intensive model with strong revenue expansion but a current inability to distribute income to shareholders, relying instead on cash flow generation and potential future profitability to support its capital structure.